IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Decreased by Twinbeech Capital LP

Twinbeech Capital LP cut its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 44.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 87,802 shares of the company's stock after selling 71,664 shares during the period. Twinbeech Capital LP owned approximately 0.10% of IDEAYA Biosciences worth $2,257,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. FMR LLC lifted its position in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after acquiring an additional 327,498 shares in the last quarter. Janus Henderson Group PLC lifted its position in IDEAYA Biosciences by 13.5% during the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after acquiring an additional 695,263 shares in the last quarter. Vanguard Group Inc. lifted its position in IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after acquiring an additional 282,936 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in IDEAYA Biosciences by 5.5% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after acquiring an additional 142,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in IDEAYA Biosciences by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after acquiring an additional 43,226 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Up 2.2%

Shares of IDYA traded up $0.41 during trading on Tuesday, reaching $19.23. The company's stock had a trading volume of 252,063 shares, compared to its average volume of 1,000,268. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -5.85 and a beta of 0.26. The company has a fifty day moving average of $17.67 and a two-hundred day moving average of $21.71.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the company posted ($0.53) earnings per share. As a group, equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. JPMorgan Chase & Co. upped their target price on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research report on Thursday, May 22nd. Stephens reaffirmed an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.